This announcement is a separate document:
泰凌醫藥：(1) 有關商業化權利許可的非常重大收購事項；(2) 建議按顧問協議根據特別授權發行代價股份；及(3) 股東特別大會通告
NT PHARMA: (1) VERY SUBSTANTIAL ACQUISITION IN RELATION TOTHE LICENSING OF COMMERCIALISATION RIGHTS;(2) PROPOSED ISSUANCE OF CONSIDERATION SHARES UNDERSPECIFIC MANDATE PURSUANT TO CONSULTANCY AGREEMENTS;AND(3) NOTICE OF EGM
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.